Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q02161
UPID:
RHD_HUMAN
Alternative names:
RHXIII; Rh polypeptide 2; Rhesus D antigen
Alternative UPACC:
Q02161; Q02162; Q07618; Q16147; Q16235; Q16355; Q5VSK0; Q5XLS9; Q5XLT1; Q5XLT2; Q9NPK0; Q9UQ20; Q9UQ21; Q9UQ22; Q9UQ23
Background:
The Blood group Rh(D) polypeptide, also known as RHXIII, Rh polypeptide 2, or Rhesus D antigen, plays a crucial role in the erythrocyte membrane. It is believed to be part of an oligomeric complex, which likely facilitates transport or channel functions, essential for red blood cell integrity and function.
Therapeutic significance:
The Rh(D) polypeptide is pivotal in the development of Hemolytic disease of the fetus and newborn, RH-induced, a condition where maternal antibodies target fetal red cells. Understanding the role of Blood group Rh(D) polypeptide could open doors to potential therapeutic strategies, offering hope for preventing or treating this condition.